Jianmin Fang, RemeGen CEO (RemeGen)
ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can't
If a record IPO wasn’t enough to put RemeGen on the map, perhaps a deal with Seagen — sporting $200 million in cash — might.
At the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
